Fortunately, with combination therapy, better results were attained in clinical studies, best response was complete remission in phase I/II for myeloma when using the combination of pomalidomide, bortezomib, dexamethasone and the granulocyte colony-stimulating factor (G-CSF) filgrastim. This evidence concerns the gene CSF3 and plasma cell myeloma.